Prime Minister Narendra Modi is predicted to carry virtual meetings with chief ministers and different representatives of states and union territories on Tuesday to overview the COVID-19 situation and focus on technique for vaccine distribution. Even because the nationwide every day COVID-19 case rely has remained beneath 50,000 for a while, many city centres have witnessed a surge, forcing enforcement of a number of measures and curfews in some cities.
Modi is more likely to attend two again to again meetings, one with eight states with excessive caseloads and one other with states and UTs to debate vaccine distribution technique, sources advised information company PTI. He has held plenty of virtual meetings with states over the coronavirus situation.
The central authorities has additionally been putting in measures for fast and efficient distribution of coronavirus vaccine when it turns into accessible. Five vaccine candidates are in superior levels of improvement in India, out of which 4 are in Phase II/III and one is in Phase-I/II trials.
Meanwhile, specialists have recognized logistics and provide as among the challenges for COVID-19 vaccine distribution. “There is no adult vaccination programme in the country except tetanus for pregnant women. Even immunisation of children had its share of difficulties with many people not vaccinating, Dr. Rakesh Mishra, Director of CSIR-Centre for Cellular and Molecular Biology (CCMB) said. He said most vaccines may require at least two doses, possibly the second one to be administered after a certain number of days, which increases difficulties in logistics and supply. The vaccines of some companies require a minus 70 degree cold chain which would be tough to arrange beyond major cities, he told PTI. Mishra said a major concern was that it would not be known till two or three years whether a vaccine was really good or not for long term protection
The Serum Institute of India is conducting phase-3 trial of the Oxford vaccine,while that of the indigenously developed COVAXIN of Hyderabad-based Bharat Biotech and the Indian Council of Medical Research (ICMR) has already begun. Dr Reddy’s Laboratories would conduct the phase 2/3 human clinical trials of the Russian COVID-19 vaccine, Sputnik V, in India. Also, the Biological E Ltd has started Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India.
Pfizer Inc. and BioNTech SE have announced that their vaccine candidate was found to be 95 per cent effective in preventing COVID-19, while Modernahas claimed that its vaccine candidate was found to have an efficacy of nearly 94.5 per cent.